Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 10/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.60 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.60 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.58 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.58 |
| ▸ | FABP4 | P15090 | 4/20 | 0.57 |
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobenzarit SCHEMBL1479150 | 1.00 | GRIK1 (0.61) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| Lobenzarit SCHEMBL187951 | 0.98 | GRIK1 (0.63) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| Lobenzarit SCHEMBL30753983 | 0.98 | GRIK1 (0.63) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| Lobenzarit SCHEMBL9621335 | 0.97 | GRIK1 (0.61) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| Lobenzarit SCHEMBL29453054 | 0.97 | GRIK1 (0.61) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL6140792 | 0.90 | FABP4 (0.62) | GRIK1AKR1C3AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL11603313 | 0.89 | GRIK1 (0.62) | GRIK1AKR1C3AKR1C2MEN1USP2 | |
| SCHEMBL14576292 | 0.89 | GRIK1 (0.73) | GRIK1AKR1C3FTOPBRM1FABP4 | |
| SCHEMBL30611313 | 0.89 | GRIK1 (0.73) | GRIK1AKR1C3FTOPBRM1FABP4 | |
| SCHEMBL16489012 | 0.89 | EGFR (0.66) | GRIK1AKR1C3AKR1B10AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3819 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021413-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2021041776-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-03-04 | — | — | WO | claimed |
| EP-2933267-A1 | HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA | AbbVie Biotechnology Ltd (BM) | 2015-10-21 | — | — | EP | claimed |
| EP-2930186-A1 | HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA | AbbVie Biotechnology Ltd (BM) | 2015-10-14 | — | — | EP | claimed |
| EP-2930187-A1 | HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA | AbbVie Biotechnology Ltd (BM) | 2015-10-14 | — | — | EP | claimed |
| EP-2930185-A1 | HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA | AbbVie Biotechnology Ltd (BM) | 2015-10-14 | — | — | EP | claimed |
| US-8778913-B2 | Antimicrobial compositions for treating microbial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | claimed |
| US-20140154302-A1 | ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | THE UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (US) | 2014-06-05 | — | — | US | claimed |
| CN-103275221-A | Human antibodies that bind human tnf alpha | ABBOTT BIOTECH LTD | 2013-09-04 | — | — | CN | claimed |
| CN-102755646-A | Medicament for treating TNF alpha related disorder | ABBOTT BIOTECH LTD | 2012-10-31 | — | — | CN | claimed |
| CN-100429232-C | Vaughan Tristan J. | ABBOTT BIOTECH LTD (BM) | 2008-10-29 | — | — | CN | claimed |
| WO-2007133712-A2 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-22 | — | — | WO | claimed |
| EP-1738759-A1 | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | SuperGen, Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| US-20050118180-A1 | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | SUPERGEN, INC. | 2005-06-02 | — | — | US | claimed |
| EP-0929578-B1 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha | BASF AG (DE) | 2003-05-02 | — | — | EP | claimed |
| EP-1285930-A2 | Human antibodies that bind human TNFalpha | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-26 | — | — | EP | claimed |
| EP-1276479-A2 | INHIBITION OF ABNORMAL CELL PROLIFERATION WITH CAMPTOTHECIN AND COMBINATIONS INCLUDING THE SAME | SuperGen, Inc. (US) | 2003-01-22 | — | — | EP | claimed |
| US-20020111362-A1 | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | SUPERGEN, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2001080843-A2 | INHIBITION OF ABNORMAL CELL PROLIFERATION WITH CAMPTOTHECIN AND COMBINATIONS INCLUDING THE SAME | SUPERGEN, INC. (US) | 2001-11-01 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |